Business Wire

Alliance to End Plastic Waste Partners with ASASE Foundation

7.5.2020 14:00:00 EEST | Business Wire | Press release

Share

The Alliance to End Plastic Waste (the Alliance) today announced a partnership with the ASASE Foundation to support women entrepreneurs working to reduce plastic litter in the community. The initiative called Closing the Loop uses a circular economy model to enable local communities to benefit from discarded plastic waste by collecting, reprocessing and reselling it.

Closing the Loop kicks off the Alliance’s support for projects based in Africa. It was first launched by ASASE in 2018 to provide seed money to equip a plastic waste reprocessing plant and offer technical and business management training to women entrepreneurs to run the recycling plant for profit. In the first twelve months, the project created eight jobs within the community and diverted 35 (metric) tons of plastic from waste. By partnering with the Alliance, the capacity of the reprocessing plant will increase to divert 2,000 (metric) tons of plastic waste per year and create even more jobs.

“A key pillar of ending plastic waste in the environment is the sustainable impact it will bring to the well-being of local communities. Our partnership with ASASE is especially meaningful because Closing the Loop is the right step towards a circular economy model. It directly benefits those living in areas which don’t have access to plastic waste collection and sorting systems. This initiative is a simple but scalable action, supporting the inspiring women of Ghana who are building communities towards a path to end plastic waste in the environment,” said Jacob Duer, President and CEO, Alliance to End Plastic Waste.

“What we value most in our partnership with the Alliance to End Plastic Waste is the access to the expertise in waste management, which we can leverage now in our project, effectively multiplying the impact of the funding provided by the Alliance to our project,” comments Dana Mosora, ASASE Foundation Founder and Managing Director.

The partnership has also opened the possibility to bring in expertise from academic partner, the Swiss Federal Institute of Technology, in areas of developing new end market applications and concepting a new financing system for the management of plastic waste in Ghana.

The recycling plant processes a range of plastic waste from water sachets (LDPE) to shampoo and detergent bottles (HDPE) and large cooking oil containers (HDPE), converting it into regrinds. The regrinds are then sold to recyclers to make items such as pavement blocks, sheets for construction and basins and liners, most of which goes back into the community.

About:

The Alliance to End Plastic Waste is a not-for-profit organization bringing together industry, government, communities, and civil society in the fight to end plastic waste.

ASASE Foundation enables Ghanaian women entrepreneurs to play a key role in cashing-in on the plastic waste trash of Accra for the benefit of their own communities.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lianne Mason
+65 91002437
Lianne.mason@endplasticwaste.org

Cassandra Cheong
+65 9827 2056
Cassandra.cheong@endplasticwaste.org

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN ® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 09:00:00 EEST | Press release

Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month 6 as the primary endpoint. Secondary endpoints include changes in monthly headache days, acute medication days and migraine frequency during two-week periods at the end of each injection cycle. “Achieving patient recruitment for both MINT-C and MINT-E six months ahead of plan is an important milestone for our XEOMIN® migraine preven

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 08:10:00 EEST | Press release

Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Malaysia 2026–2027 (VM2026–2027), this partnership merges Tourism Malaysia’s destination marketing with Alipay+’s global wallet ecosystem and AI capabilities. It aims to create a highly intelligent digital journey, connecti

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 08:00:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe atopic dermatitis, sustained through Week 52.1 The results will be presented at The Pediatric Dermatology Research Alliance (PeDRA) Annual Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014705800/en/ Up to 25% of children are affected by atopic dermatitis - the most common inflammatory skin disorder in this population - and around one-third of these children have moderate-to-severe disease.11,12 Atopic dermatitis creates a high burden for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school, and social confidence.2-8 Despite the high prevalence and significant burden, treatment options are

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 03:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re excited at the potential to fundamentally change how NT1 is managed across Japan and China,” said Giles Platford, president, International, Takeda. “We’ve heard from patients how ORZEYFUL has improved their daily functioning and quality of life, enormously meaningful outcomes for a condition known to impact many aspects of a person’s life, including work, education and social interactions.”1,2,3,4,5 NT1 is a chronic, rare neurological disease driven by orexin deficiency. People experience a range of symptoms including excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), disr

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 03:10:00 EEST | Press release

Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to expand treatment options for patients with IBD.2,3 On October 18, Celltrion will host a symposium titled "Navigating the Treatment Journey with Subcutaneous Infliximab Across Clinical Scenarios," Chaired by Professor Peter M. Irving of King's College London, UK, a leading IBD expert. Celltrion will also host two MTE sessions at its booth. In the firs

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye